MDCX logo

MEDICUS PHARMA LTD

MDCXNASDAQ
πŸ† #5037 by market capUS Equity
$2.45β–Ό $0.12 (βˆ’4.67%)
Market closed Β· at close
πŸ””
Track MDCX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.7%
7dβ–Ό 7.2%
14dβ–Ό 26.0%
30dβ–Ό 68.9%
ytdβ–Ό 96.8%
1yβ–Ό 97.9%
🏦Market Cap
$5M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$2.45 – $2.47
52-Week Range
$2.41 – $139.00
Volume (shares)
404
Avg Volume (shares)
β€”
Shares Outstanding
1.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-1.81
Dividend Yield
β€”
Dilution (1yr)
+113.1%
MDCX logo

MEDICUS PHARMA LTD

MDCX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$18Mβ–² +64.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$23Mβ–² +122.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
504Kβ–² +113.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2Mβ–Ό βˆ’$1M YoY
StockOtter Β· stockotter.space

About MEDICUS PHARMA LTD

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.